Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and Visionology, a membership-based online eye health and medication platform. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was founded in 1998 and is headquartered in San Diego, California.
IPO Year:
Exchange: NASDAQ
Website: harrowinc.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/4/2024 | $73.00 → $69.00 | Buy | B. Riley Securities |
| 4/11/2024 | $24.00 | Buy | Craig Hallum |
| 9/8/2022 | $17.00 | Buy | B. Riley Securities |
| 10/14/2021 | $16.00 | Buy | B. Riley Securities |
| 9/24/2021 | $15.00 | Buy | Aegis Capital |
| 7/2/2021 | $14.25 | Buy | Ladenburg Thalmann |
Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that Amir H. Shojaei, PharmD, PhD, has joined Harrow as Chief Scientific Officer (CSO). With a remarkable career spanning 28 years in life sciences, Dr. Shojaei brings deep expertise in clinical development, regulatory affairs, and the commercialization of biopharmaceutical and biologic products, including groundbreaking work in anterior and posterior segment ophthalmic indications. Dr. Shojaei most recently served as CSO and Executive Vice President of Clinical Development at AsclepiX Therapeutics, where he spearheaded the development of innovative therapies for neovascular retinal disorders. P
Harrow (NASDAQ:HROW), a leading U.S. eyecare pharmaceutical company, is pleased to announce the appointment of Greg DiPasquale as Senior Vice President, Head of Commercial, effective immediately. DiPasquale will oversee sales, marketing, and sales operations for Harrow's rapidly growing portfolio of branded ophthalmic products. This new role reflects Harrow's commitment to enhancing its leadership structure to support the Company's continued growth. John Saharek, Harrow's Chief Commercial Officer and Chief Executive Officer of ImprimisRx, will continue to oversee Harrow's commercial business, focusing on the day-to-day management of Harrow's market‑leading compounded division. DiPasquale
Harrow (NASDAQ:HROW), a leading U.S. eyecare pharmaceutical company, today announced the appointment of Mark Mannebach, Ph.D., R.Ph. as Head of Regulatory Affairs and Pharmacovigilance, responsible for overseeing and managing all regulatory related submissions and strategy related to the Company's portfolio of new and existing products. Dr. Mannebach's successful 30-year career in the pharmaceutical industry, much of which was focused in ophthalmology, includes leadership roles in regulatory affairs, quality assurance, program management and pharmaceutical product development. "Dr. Mannebach brings to Harrow decades of regulatory and clinical expertise and leadership –specifically in ophth
Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that Amir H. Shojaei, PharmD, PhD, has joined Harrow as Chief Scientific Officer (CSO). With a remarkable career spanning 28 years in life sciences, Dr. Shojaei brings deep expertise in clinical development, regulatory affairs, and the commercialization of biopharmaceutical and biologic products, including groundbreaking work in anterior and posterior segment ophthalmic indications. Dr. Shojaei most recently served as CSO and Executive Vice President of Clinical Development at AsclepiX Therapeutics, where he spearheaded the development of innovative therapies for neovascular retinal disorders. P
OSRX, Inc. today expressed its profound disappointment with the recent jury verdict in the case of ImprimisRx, LLC v. OSRX, Inc. The company believes the decision to be unjust and not based on the facts presented during the trial. Despite this setback, OSRX remains resolute in its commitment to challenge this outcome and address the significant issues that persist. "Leading up to the trial, OSRX won summary judgment on ImprimisRx's false advertising claims, and ImprimisRx abandoned its copyright claim," said Dylan Liddiard of Wilson Sonsini Goodrich & Rosati, who defended OSRX. "The Court did not enter final judgment based on the jury verdict, as there remain significant legal and equitab
Jury in Trademark Infringement Case Finds in Favor of ImprimisRx Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced a favorable jury verdict in the case of ImprimisRx, LLC v. OSRX, Inc. ImprimisRx, a wholly owned subsidiary of Harrow, brought the lawsuit to a jury trial in a San Diego, California, federal court alleging willful acts of trademark infringement against OSRX, Inc. and its related party, Ocular Science, Inc. An eight-person jury in the United States District Court for the Southern District of California unanimously validated the entirety of ImprimisRx's subject trademark estate and found OSRX, Inc. or Ocular Science, Inc. acted with
MELT-300 Demonstrates Statistically Superior Compared to Both Sublingual Midazolam (P=0.009) and Placebo (P<0.001) for Providing Successful Procedural Sedation Proportion of Patients Requiring Rescue Sedation Was Nearly Two-Fold Higher for Sublingual Midazolam Compared with MELT-300 (P=0.003) MELT-300 Had a Favorable Safety Profile That Was Generally Comparable to Placebo Melt Pharmaceuticals, Inc. ("Melt"), a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced positive topline results of its pivotal Phase 3 study evaluating the safety and efficacy of its lead product candidate, MELT‑300, a non-IV, non-opioid tablet for procedural
Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following three investor conferences: Craig-Hallum 15th Annual Alpha Select Conference (Sheraton New York Times Square Hotel) November 19, 2024 1x1 Meetings Only BTIG 4th Annual Ophthalmology Day (Virtual) December 2, 2024 1x1 Virtual Meetings Only Piper Sandler 36th Annual Healthcare Conference (The Lotte New York Palace) December 3-5, 2024 Company will host a Fireside Chat at 8:00 a.m. ET on December 4, 2024 The Company will conduct one-on-one meetings at each conference. Investors interested in meeting with management during conferences should con
Third Quarter 2024 and Recent Selected Highlights: Revenues increased 44% from $34.3 million in the prior-year quarter to $49.3 million GAAP net loss of $(4.2) million Adjusted EBITDA of $8.8 million Operating cash flow of $3 million Cash and cash equivalents of $72.6 million as of September 30, 2024 VEVYE® total prescriptions up 55% over the second quarter of 2024 IHEEZO® customer unit demand volume up 15% over the second quarter of 2024 TRIESENCE® October 2024 relaunch underway Expansion of access and affordability through multiple new partnerships First major Medicare Part D win for VEVYE with major plan sponsors Fourth quarter revenue indicates meaningfu
New Partnership with GoodRx to Lower Costs for Uninsured and Underinsured Patients Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced an innovative initiative to expand access and affordability for its ophthalmic pharmaceutical products. This effort includes a program of targeted price reductions for several Harrow products and a strategic partnership with GoodRx (NASDAQ:GDRX), the leading prescription savings platform in the U.S., providing patients with discounts on select Harrow products. This initiative reflects Harrow's ongoing commitment to making essential, sight-saving medications accessible and affordable. A core component of Harrow's
Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced its first major market access wins in the 2025 Medicare Part D Prescription Drug Program. Starting January 1, 2025, VEVYE will be included in key formularies managed by major plan sponsors such as Express Scripts, Cigna, Kaiser Permanente, and CVS Caremark. In the aggregate, these sponsors represent over 25 million Medicare Part D beneficiaries. In addition to Medicare Part D, VEVYE has achieved broad coverage across other major insurance programs, including 100% of U.S. Medicaid programs and 60% of commercial insurance coverage. This breadth of coverage underscores Harrow's commitment to ensuri
Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced the nationwide launch of a new digital patient access solution in collaboration with Asembia, a leading provider of specialty pharmacy and patient support hub services. This multi-year exclusive partnership is designed to expand access to Harrow's ophthalmic branded products, including FLAREX®, ILEVRO®, MAXIDEX®, MAXITROL®, NATACYN®, NEVANAC®, TOBRADEX® ST, VERKAZIA®, VEVYE®, VIGAMOX®, and ZERVIATE®, by simplifying the prescribing process for eyecare professionals and improving both accessibility and affordability for patients. ASPN Pharmacies is Asembia's non-dispensing pharmacy, specializing in
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on November 14, 2024 Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the third quarter ended September 30, 2024, on Wednesday, November 13, 2024, after the market close. The Company will also post its third quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Thursday, November 14, 2024, to discuss the results and provide a business update. Conference Call Information Participants can access the live conferen
SC 13G/A - HARROW, INC. (0001360214) (Subject)
SC 13G/A - HARROW, INC. (0001360214) (Subject)
SC 13G/A - HARROW, INC. (0001360214) (Subject)
SC 13G - HARROW, INC. (0001360214) (Subject)
SC 13G/A - HARROW, INC. (0001360214) (Subject)
SC 13G - HARROW, INC. (0001360214) (Subject)
SC 13G - HARROW, INC. (0001360214) (Subject)
SC 13D/A - HARROW HEALTH, INC. (0001360214) (Subject)
SC 13G/A - HARROW HEALTH, INC. (0001360214) (Subject)
SC 13G - HARROW HEALTH, INC. (0001360214) (Subject)
Third Quarter 2024 and Recent Selected Highlights: Revenues increased 44% from $34.3 million in the prior-year quarter to $49.3 million GAAP net loss of $(4.2) million Adjusted EBITDA of $8.8 million Operating cash flow of $3 million Cash and cash equivalents of $72.6 million as of September 30, 2024 VEVYE® total prescriptions up 55% over the second quarter of 2024 IHEEZO® customer unit demand volume up 15% over the second quarter of 2024 TRIESENCE® October 2024 relaunch underway Expansion of access and affordability through multiple new partnerships First major Medicare Part D win for VEVYE with major plan sponsors Fourth quarter revenue indicates meaningfu
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on November 14, 2024 Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the third quarter ended September 30, 2024, on Wednesday, November 13, 2024, after the market close. The Company will also post its third quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Thursday, November 14, 2024, to discuss the results and provide a business update. Conference Call Information Participants can access the live conferen
Second Quarter 2024 and Recent Selected Highlights: Record revenues of $48.9 million GAAP net loss of $(6.5) million Adjusted EBITDA of $8.8 million Cash and cash equivalents of $71.0 million as of June 30, 2024 IHEEZO® customer unit demand volume increased by 98% from the first quarter of 2024 IHEEZO supply agreements total 24 agreements to date in 2024, including a recent win with the largest and highest volume U.S. retina practice group VEVYE® total prescriptions increased by 212% from the first quarter of 2024 Anterior Segment revenues up over 40% from the first quarter of 2024 Record quarterly revenues from Harrow's ImprimisRx subsidiary Harrow (NASDAQ:HRO
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on August 8, 2024 Harrow (NASDAQ:HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will report its financial results for the second quarter ended June 30, 2024, on Wednesday, August 7, 2024, after the market close. The Company will also post its second quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Thursday, August 8, 2024, to discuss the results and provide a business update. Conference Call Information Participants can access the live conference call via webcast
First Quarter 2024 and Recent Selected Highlights: Revenues of $34.6 million, a 33% increase over the $26.1 million realized in the prior-year quarter. Received confirmation from the Centers for Medicare & Medicaid Services (CMS) on March 20 that IHEEZO is separately reimbursable for unilateral and bilateral in-office procedures, retroactive to January 1, 2024. Recently signed IHEEZO supply agreements with seven multi-practice strategic accounts. U.S. Patent and Trademark Office recently granted new IHEEZO patent claims with an expiry through 2039. Sequential month-over-month growth in VEVYE total prescriptions, new prescriptions, prescribers, and refills. Covered lives fo
Company to Host Conference Call to Discuss Results at 8:00 a.m. ET on May 14, 2024 Harrow (NASDAQ:HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the first quarter ended March 31, 2024, on Monday, May 13, 2024, after the market close. The Company will also post its first quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Tuesday, May 14, 2024, to discuss the results and provide a business update. Conference Call Details: Date: Tuesday, May 14, 2024 Time: 8:00 a.m. Ea
Full-Year 2023 Highlights: Revenues of $130.2 million, an increase of 47% over 2022 revenues of $88.6 million. GAAP net loss of $(24.4 million) compared with $(14.1 million) for the prior-year period. Adjusted EBITDA of $28.1 million, an increase of 116% over 2022 Adjusted EBITDA of $13.0 million. Cash from operating activities of $3.8 million. GAAP gross margin was 70% compared with 71% in the prior-year period. Core gross margin was 77% compared with 73% in the prior-year period. Cash and cash equivalents of $83 million, including investments in Eton Pharmaceuticals, as of December 31, 2023. Harrow (NASDAQ:HROW), a leading U.S. eyecare pharmaceutical company, annou
Company to Host Conference Call to Discuss Results at 8:00 a.m. ET on March 20, 2024 Harrow (NASDAQ:HROW), a leading North American eyecare pharmaceutical company, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2023, on Tuesday, March 19, 2024, after the market close. The Company will also post its fourth quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Wednesday, March 20, 2024, to discuss the results and provide a business update. Conference Call Details: Date: Wednesday, March 20, 2
Third Quarter 2023 and Recent Selected Highlights: Record revenues of $34.3 million, an increase of 50% over $22.8 million in the prior-year quarter and an increase of 2% over $33.5 million in the sequential quarter. GAAP net loss of $(4.4 million). Adjusted EBITDA of $9.2 million, an increase of 270% over $2.5 million in the prior‑year quarter. GAAP gross margin was flat at 71%, year-over-year. Core gross margin improved to 78% over the prior year's 72%. Cash and cash equivalents of $65.6 million as of September 30, 2023. Harrow Completes Transfer of NDAs and Launches FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, and ZERVIATE® in the U.S. Harrow (NASDAQ:HROW), a leadi
Harrow (NASDAQ:HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the third quarter ended September 30, 2023, on Monday, November 13, 2023, after the market close. The Company will also post its third quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 4:45 p.m. Eastern Time to discuss the results and provide a business update. Conference Call Details: Date: Monday, November 13, 2023 Time: 4:45 p.m. Eastern time Participant Dial-in: 1-833-953-2434 (U.S.) 1-412-317-5763 (International)
B. Riley Securities reiterated coverage of Harrow with a rating of Buy and set a new price target of $69.00 from $73.00 previously
Craig Hallum initiated coverage of Harrow with a rating of Buy and set a new price target of $24.00
B. Riley Securities resumed coverage of Harrow Health with a rating of Buy and set a new price target of $17.00
B. Riley Securities resumed coverage of Harrow Health with a rating of Buy and set a new price target of $16.00
Aegis Capital initiated coverage of Harrow Health with a rating of Buy and set a new price target of $15.00
Ladenburg Thalmann initiated coverage of Harrow Health with a rating of Buy and set a new price target of $14.25
4 - HARROW, INC. (0001360214) (Issuer)
3 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW, INC. (0001360214) (Issuer)
4 - HARROW HEALTH, INC. (0001360214) (Issuer)
10-Q - HARROW, INC. (0001360214) (Filer)
8-K - HARROW, INC. (0001360214) (Filer)
8-K - HARROW, INC. (0001360214) (Filer)
8-K - HARROW, INC. (0001360214) (Filer)
10-Q - HARROW, INC. (0001360214) (Filer)
8-K - HARROW, INC. (0001360214) (Filer)
8-K - HARROW, INC. (0001360214) (Filer)
8-K - HARROW, INC. (0001360214) (Filer)
10-Q - HARROW, INC. (0001360214) (Filer)
8-K - HARROW, INC. (0001360214) (Filer)